Press release
Obesity Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Merck, Alizyme, Bayer, GlaxoSmithKline, Bristol-Myers Squibb, Currax Pharma
The Obesity Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Obesity Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/obesity-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Obesity Market.
Some of the key takeaways from the Obesity Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Obesity treatment therapies with a considerable amount of success over the years.
*
Obesity companies working in the treatment market are D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, Oral Novo Nordisk, and others, are developing therapies for the Obesity treatment
*
Emerging Obesity therapies in the different phases of clinical trials are- DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Tirzepatide, Semaglutide, and others are expected to have a significant impact on the Obesity market in the coming years.
*
In April 2024, Eli Lilly has reportedly initiated Phase III clinical trials for the oral medication orforglipron in India. This oral drug aims to offer a non-injectable option for weight loss, particularly targeting patients with Type 2 diabetes and those who are overweight or obese with a heightened risk of cardiovascular diseases.
*
In June 2023, Comprehensive findings from SURMOUNT-2, a phase 3 clinical trial assessing the effectiveness and safety of Eli Lilly and Company's tirzepatide (at doses of 10 mg and 15 mg) for managing weight in individuals dealing with obesity or overweight and type 2 diabetes, indicated that tirzepatide resulted in greater weight loss compared to the placebo for both dosage levels. These results were shared at a symposium during the American Diabetes Association's Registered (ADA) 83rd Scientific Sessions and were concurrently published in The Lancet.
Obesity Overview
Obesity is acknowledged as a chronic or non-communicable ailment, characterized by a multifaceted and intricate nature, affecting individuals primarily due to excessive adiposity or body fat rather than solely body size. This condition can result in metabolic manifestations beyond physical appearance. The undesirable increase in body weight, contributing to obesity and overweight, stands as a primary factor driving the global surge in non-communicable diseases. Consequently, it is categorized as a non-communicable disease.
Get a Free Sample PDF Report to know more about Obesity Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/obesity-pipeline-insight [https://www.delveinsight.com/report-store/obesity-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Obesity Drugs Under Different Phases of Clinical Development Include:
*
DD03: D&D Pharmatech
*
AX-0601: ProQR Therapeutics
*
NPM 139: Nano Precision Medical
*
BK-1701: Bukwang Pharmaceutical
*
CBW-520: Caliway Biopharmaceutics
*
YH34160: Yuhan
*
TERN-601: Terns Pharmaceuticals
*
Thermostem: BioRestorative Therapies
*
SCO-267: SCOHIA PHARMA
*
CT-181: Click Therapeutics
*
HM15136: Hanmi Pharmaceuticals
*
NNC0480-0389: Novo Nordisk
*
EMP-16: Empros Pharma
*
CT-868: Carmot Therapeutics
*
Tirzepatide: Eli Lilly and Company
*
Semaglutide: Oral Novo Nordisk
Obesity Route of Administration
Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical
Obesity Molecule Type
Obesity Products have been categorized under various Molecule types, such as
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
Obesity Pipeline Therapeutics Assessment
*
Obesity Assessment by Product Type
*
Obesity By Stage and Product Type
*
Obesity Assessment by Route of Administration
*
Obesity By Stage and Route of Administration
*
Obesity Assessment by Molecule Type
*
Obesity by Stage and Molecule Type
DelveInsight's Obesity Report covers around 130+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Obesity product details are provided in the report. Download the Obesity pipeline report to learn more about the emerging Obesity therapies [https://www.delveinsight.com/sample-request/obesity-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Obesity Therapeutics Market include:
Key companies developing therapies for Obesity are - Alizyme, Bayer AG, Bristol-Myers Squibb, Currax Pharmaceuticals LLC, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co. Inc., Norgine BV, Novo Nordisk AS, Pfizer Inc., Rhythm Pharmaceuticals, Takeda Pharmaceuticals, Vivus Inc., Zafgan, Zydus Cadila, and others.
Obesity Pipeline Analysis:
The Obesity pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Obesity with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obesity Treatment.
*
Obesity key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Obesity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obesity market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Obesity drugs and therapies [https://www.delveinsight.com/sample-request/obesity-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Obesity Pipeline Market Drivers
*
Rise in prevalence of Obesity, growing Research and Development Activities to develop novel therapies to treat obesity, changing lifestyle patterns are some of the important factors that are fueling the Obesity Market.
Obesity Pipeline Market Barriers
*
However, challenges associated with the discovery of anti-obesity drugs, economic burden associated with obesity and other factors are creating obstacles in the Obesity Market growth.
Scope of Obesity Pipeline Drug Insight
*
Coverage: Global
*
Key Obesity Companies: D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, Oral Novo Nordisk, and others
*
Key Obesity Therapies: DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Tirzepatide, Semaglutide, and others
*
Obesity Therapeutic Assessment: Obesity current marketed and Obesity emerging therapies
*
Obesity Market Dynamics: Obesity market drivers and Obesity market barriers
Request for Sample PDF Report for Obesity Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/obesity-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Obesity Report Introduction
2. Obesity Executive Summary
3. Obesity Overview
4. Obesity- Analytical Perspective In-depth Commercial Assessment
5. Obesity Pipeline Therapeutics
6. Obesity Late Stage Products (Phase II/III)
7. Obesity Mid Stage Products (Phase II)
8. Obesity Early Stage Products (Phase I)
9. Obesity Preclinical Stage Products
10. Obesity Therapeutics Assessment
11. Obesity Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Obesity Key Companies
14. Obesity Key Products
15. Obesity Unmet Needs
16 . Obesity Market Drivers and Barriers
17. Obesity Future Perspectives and Conclusion
18. Obesity Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=obesity-pipeline-and-clinical-trials-assessment-2024-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-merck-alizyme-bayer-glaxosmithkline-bristolmyers-squibb-currax-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Obesity Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Merck, Alizyme, Bayer, GlaxoSmithKline, Bristol-Myers Squibb, Currax Pharma here
News-ID: 3545229 • Views: …
More Releases from ABNewswire
Denver's Best Appliance Repair Responds to Rising Demand for Emergency Appliance …
Denver's Best Appliance Repair expands emergency services across the Denver metro with same-day repairs, 7-day availability, 5-year parts warranty, and professional licensed technicians serving residential and commercial clients.
Household appliance failures don't follow a schedule. When a refrigerator stops cooling in the middle of summer or a washing machine floods a basement on a Sunday evening, families need immediate help. Denver's Best Appliance Repair has responded to this growing need by…
Oak Hill Clinic Reaches 30,000 Client Milestone with Results-Driven Deep Tissue …
Deep Relief in Oak Hill, Austin, has served 30,000 clients through specialized massage, chiropractic, and acupuncture care. The clinic accepts insurance and focuses on results-driven treatments for pain relief.
Deep Relief, an Oak Hill-based wellness clinic, has achieved a significant milestone by serving more than 30,000 clients seeking Relief from chronic pain, muscle tension, and mobility issues. The clinic's success stems from its commitment to advanced, results-focused bodywork that goes beyond…
Vertex Fleet Expands Nationwide Network to Combat Growing Trailer Drop Yard Shor …
Vertex Fleet announces major expansion of secure parking facilities nationwide, addressing the critical shortage of commercial vehicle storage with 15+ new locations featuring 24/7 security and technology-driven access.
The freight and logistics industry faces a mounting crisis as demand for secure parking spaces continues to outpace supply across the United States. Vertex Fleet [https://www.vertexfleet.com/], a leading provider of industrial outdoor storage solutions, has announced significant expansion plans to address this critical…
HVAC in Denver Sees Service Enhancement as Denver's Best Heating and AC Repair L …
Denver's Best Heating and AC Repair expands 24/7 emergency services across 23 metro cities, offering A+ rated heating, cooling, and commercial HVAC solutions with rapid response times and multi-brand expertise.
Denver's Best Heating and AC Repair [https://www.denversbestheatingandacrepair.com/]has expanded its service capabilities to meet growing demand for reliable heating and cooling solutions across the Denver Metro area. The A+ rated contractor now provides 24/7 emergency response services to 23 cities, addressing critical…
More Releases for Obesity
Anti-Obesity Drugs Market Grows Rapidly, Driven by Obesity Rates and Therapeutic …
Anti-Obesity Drugs Market valued at USD 5.9 Bn in 2024, growing at 16.5% CAGR to reach USD 20.02 Bn by 2032. Driven by GLP-1 therapies and rising obesity rates.
Anti Obesity Drugs Market Overview:
The anti-obesity drugs market is undergoing significant transformation as awareness about obesity-related health risks rises globally. With growing concern over lifestyle-related disorders, there is an increasing emphasis on medical intervention as a complement to traditional weight management strategies.…
Fuzzle joins The Obesity Society & The Obesity Action Coalition; Promotes Habit- …
Building healthy, sustainable habits for long-term weight management success.
Tampa, FL - March 18, 2025 - Fuzzle, an emerging leader in the wellness landscape, is pleased to announce that it's now a Member of The Obesity Society, as well as the Obesity Action Coalition, marking a new milestone in the company's mission to transform how individuals approach weight loss.
Image: https://www.globalnewslines.com/uploads/2025/03/77da787ae98a633847c70fc22e2943c7.jpg
Fuzzle supports individuals in their wellness journey through non-invasive, drug-free strategies. With…
Pediatric Obesity Management Market - Healthy Habits for Life: Advancing Pediatr …
Newark, New Castle, USA: The "Pediatric Obesity Management Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Pediatric Obesity Management Market: https://www.growthplusreports.com/report/pediatric-obesity-management-market/8930
This latest report researches the industry structure,…
Anti-Obesity Drugs Market - From Obesity to Vitality: Leading the Way in Effecti …
Newark, New Castle, USA - new report, titled Anti-Obesity Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Anti-Obesity Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Anti-Obesity Drugs market. The report offers an overview of the market, which…
Increasing Prevalence of Obesity Driving Obesity/Bariatric Surgery Devices Marke …
The global obesity/bariatric surgery devices market revenue stood at $1.4 billion in 2016, and it is expected to rise to $2.8 billion by 2023. Furthermore, the market will progress at a CAGR of 9.9% from 2017 to 2023 (forecast period), as per the estimates of the market research company, P&S Intelligence. The major growth drivers of the market are the rising incidence of obesity, owing to unhealthy diets and lifestyle…
Fast Food and Obesity
Most of the fast food in the market contains a large quantity of sugar, #carbs and fats with a lesser quantity of vitamins and minerals. The unhealthy food ingredients in the fast food are further increased with increased portion size. The person will still consume the whole meal regardless of being completely full. People cannot stop ravishing on fast food because it is available for low cost and in close…
